Department of Biochemistry, Emory University, Atlanta, GA 30322, USA.
Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Cell Chem Biol. 2016 Jul 21;23(7):769-781. doi: 10.1016/j.chembiol.2016.06.006. Epub 2016 Jul 14.
The KDM5/JARID1 family of Fe(II)- and α-ketoglutarate-dependent demethylases removes methyl groups from methylated lysine 4 of histone H3. Accumulating evidence supports a role for KDM5 family members as oncogenic drivers. We compare the in vitro inhibitory properties and binding affinity of ten diverse compounds with all four family members, and present the crystal structures of the KDM5A-linked Jumonji domain in complex with eight of these inhibitors in the presence of Mn(II). All eight inhibitors structurally examined occupy the binding site of α-ketoglutarate, but differ in their specific binding interactions, including the number of ligands involved in metal coordination. We also observed inhibitor-induced conformational changes in KDM5A, particularly those residues involved in the binding of α-ketoglutarate, the anticipated peptide substrate, and intramolecular interactions. We discuss how particular chemical moieties contribute to inhibitor potency and suggest strategies that might be utilized in the successful design of selective and potent epigenetic inhibitors.
KDM5/JARID1 家族的 Fe(II)和α-酮戊二酸依赖性去甲基酶将组蛋白 H3 赖氨酸 4 上的甲基基团去除。越来越多的证据支持 KDM5 家族成员作为致癌驱动因子的作用。我们比较了十种不同化合物对所有四个家族成员的体外抑制特性和结合亲和力,并展示了 KDM5A 连接的 Jumonji 结构域在 Mn(II)存在下与其中八种抑制剂结合的晶体结构。所有八种结构上经过检查的抑制剂都占据了α-酮戊二酸的结合位点,但在其特定的结合相互作用上有所不同,包括参与金属配位的配体数量。我们还观察到 KDM5A 中的抑制剂诱导构象变化,特别是那些涉及α-酮戊二酸、预期的肽底物以及分子内相互作用的残基。我们讨论了特定的化学部分如何有助于抑制剂的效力,并提出了可能用于成功设计选择性和有效的表观遗传抑制剂的策略。